tiprankstipranks
Trending News
More News >
Advertisement
Advertisement
Kalaris Therapeutics reports Q2 EPS (61c), consensus (52c)
PremiumThe FlyKalaris Therapeutics reports Q2 EPS (61c), consensus (52c)
2M ago
Kalaris Therapeutics assumed with a Neutral at Piper Sandler
Premium
The Fly
Kalaris Therapeutics assumed with a Neutral at Piper Sandler
2M ago
Cautious Hold on Kalaris Therapeutics: Awaiting Key Data on TH103’s Potential in Wet AMD
Premium
Ratings
Cautious Hold on Kalaris Therapeutics: Awaiting Key Data on TH103’s Potential in Wet AMD
2M ago
Buy Rating for Kalaris Therapeutics: Promising TH103 Development and Strong Financial Position
PremiumRatingsBuy Rating for Kalaris Therapeutics: Promising TH103 Development and Strong Financial Position
5M ago
Kalaris Therapeutics reports Q1 EPS ($2.52) vs ($2.60) last year
Premium
The Fly
Kalaris Therapeutics reports Q1 EPS ($2.52) vs ($2.60) last year
5M ago
Buy Rating for Kalaris Therapeutics Driven by Promising Market Potential and Innovative TH103 Therapy
Premium
Ratings
Buy Rating for Kalaris Therapeutics Driven by Promising Market Potential and Innovative TH103 Therapy
5M ago
Kalaris Therapeutics initiated with an Outperform at William Blair
PremiumThe FlyKalaris Therapeutics initiated with an Outperform at William Blair
6M ago
Buy Rating for Kalaris Therapeutics: Promising Advancements in Retinal Vascular Disease Market
Premium
Ratings
Buy Rating for Kalaris Therapeutics: Promising Advancements in Retinal Vascular Disease Market
6M ago
Kalaris Therapeutics Appoints Leone Patterson to Board
Premium
Company Announcements
Kalaris Therapeutics Appoints Leone Patterson to Board
6M ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100